在HCC中异常的血管性信号:治疗向和耐药性
Hongtao Zhang1,2, Zhaoming Yang2, Zhengwu Jiang2
1Jishou University Zhuzhou Clinical College, Medical College, Jishou University, Zhuzhou, Hunan, China.
Frontiers in oncology
|July 3, 2025
概括
肝细胞癌 (HCC) 治疗由于复杂的瘤血管生成而面临挑战. 了解和准血管生成途径的复杂交叉,为肝癌提供了新的治疗策略.
科学领域:
- 在瘤学瘤学.
- 癌症生物学 癌症生物学
- 翻译医学是一种翻译医学.
背景情况:
- 肝细胞癌 (HCC) 是全球主要的癌症,治疗选择有限.
- 抗血管生成疗法是目前HCC管理的标准.
- 瘤血管生成对于癌症生长和转移至关重要,涉及失调的信号通路.
研究的目的:
- 为HCC.提供有关血管源性网络可塑性的机制性见解.
- 探索用于克服HCC治疗瓶的翻译策略.
- 阐明血管新生路径之间的复杂交叉,以改善治疗.
主要方法:
- 对HCC中的血管新生现有文献的综述.
- 信号通路失调和相互作用的分析.
- 针对血管生成网络的治疗策略的讨论.
主要成果:
- 血管新生是一个关键的,但复杂的过程,在HCC的发展和进展.
- 异常的血管新生信号通路表现出复杂的交叉声,影响治疗的有效性.
- 针对这些相互连接的途径具有改善HCC治疗和克服耐药性的潜力.
结论:
- 阐明血管性网络可塑性是推动HCC治疗的关键.
- 专注于途径交叉的转化策略可以克服当前的治疗局限性.
- 对这些相互作用的进一步研究可能会导致更有效的肝癌疗法.
更多相关视频
12:24A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
Published on: September 30, 2021
5.4K
08:40A Biomimetic Model for Liver Cancer to Study Tumor-Stroma Interactions in a 3D Environment with Tunable Bio-Physical Properties
Published on: August 7, 2020
6.3K
相关概念视频
Regulation of Angiogenesis and Blood Supply
2.7K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.7K
Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
mTOR Signaling and Cancer Progression
3.9K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.9K
Mitogens and the Cell Cycle
6.9K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.9K
Adaptive Mechanisms in Cancer Cells
5.9K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.9K
Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
